Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis

Singh, Pankaj Kumar; Pawar, Vivek K.; Jaiswal, Anil K.; Singh, Yuvraj; Srikanth, Cheruvu Hanumanth; Chaurasia, Mohini; Bora, Himangsu K.; Raval, Kavit; Meher, Jaya Gopal; Gayen, Jiaur R.; Dube, Anuradha; Chourasia, Manish K.

doi:10.1016/j.ijbiomac.2017.07.161

Cited by 63 publications

(57 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Poloxamer F127 is broadly utilized as an adjuvant in the medical field. . In its application as a hydrogel matrix, the poloxamer F127 solution (approximately 20–40%) maintains a liquid state at low temperatures (approximately 4–5 °C) and a gelatinous state at body temperature.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‐365 promotes the contractile phenotype of venous smooth muscle cells and inhibits neointimal formation in rat vein grafts

et al. 2019

View full text Add to dashboard Cite

The high rate of autologous vein graft failure caused by neointimal hyperplasia remains an unresolved issue in the field of cardiovascular surgery; therefore, it is important to explore new methods for protecting against neointimal hyperplasia. MicroRNA‐365 has been reported to inhibit the proliferation of vascular smooth muscle cells (SMCs). This study aimed to test whether adenovirus‐mediated miR‐365 was able to attenuate neointimal formation in rat vein grafts. We found that miR‐365 expression was substantially reduced in vein grafts following engraftment. In vitro, overexpression of miR‐365 promoted smooth muscle‐specific gene expression and inhibited venous SMC proliferation and migration. Consistent with this, overexpression of miR‐365 in a rat vein graft model significantly reduced grafting‐induced neointimal formation and effectively improved the hemodynamics of the vein grafts. Mechanistically, we identified that cyclin D1 as a potential downstream target of miR‐365 in vein grafts. Specially, to increase the efficiency of miR‐365 gene transfection, a 30% poloxamer F‐127 gel containing 0.25% trypsin was mixed with adenovirus and spread around the vein grafts to increase the adenovirus contact time and penetration. We showed that adenovirus‐mediated miR‐365 attenuated venous SMC proliferation and migration in vitro and effectively inhibited neointimal formation in rat vein grafts. Restoring expression of miR‐365 is a potential therapeutic approach for the treatment of vein graft failure. © 2019 IUBMB Life, 2019

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA‐365 promotes the contractile phenotype of venous smooth muscle cells and inhibits neointimal formation in rat vein grafts

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Current therapies used for leishmaniasis encountered some difficulties due to their high toxicity and low water solubility (8,10,(20)(21)(22)(23). Nowadays nanocarriers were successful in solving these problems (5).…”

Section: Discussionmentioning

confidence: 99%

“…Recently, nanotechnology was considered as an appropriate alternative due to the fact that we can deliver current medicines by nanosized carriers and improve bioavailability and reduce toxicity (5). In this regard, researchers have used two nanocarriers of nanochitosan (K) and anionic linear globular dendrimer (ALGD) for treatment of leishmaniasis to decrease the side effects of conventional medicines (6)(7)(8)(9)(10)(11)(12)(13). Nanochitosan is a nanocarrier with ability to decrease the drug toxicity and increase the drug solubility.…”

Section: Introductionmentioning

confidence: 99%

In Vivo Therapeutic Effects of Four Synthesized Antileishmanial Nanodrugs in the Treatment of Leishmaniasis

Mehrizi

Mosaffa

Hoseini

et al. 2018

Arch Clin Infect Dis

View full text Add to dashboard Cite

Background: Nowadays, nanocarriers are used for leishmaniasis treatment due to development of drug resistance and several side effects with conventional therapeutics. Objectives: In this study we aimed to evaluate in vivo effects of four synthesized nanodrugs including amphotericin B-nanochitosan (AK), betulinic acid-nanochitosan (BK), amphotericin B-dendrimer (AD), and betulinic acid-dendrimer (BD) in the treatment of Leishmania major infection (L. major) in mice model by using pathological analyses to choose the most effective nanodrug in leishmaniasis. Methods: The four nanodrugs efficacy in the improvement of L. major lesion in a mice model was evaluated by using pathological analyses including measurement of organs size and parasite number. Additionally, the nanodrugs toxicity was evaluated by measurement of various blood factors. Results: The histopathological results of the present study showed that BK, at the dose of 20 mg/kg, and AK, at the dose of 10 mg/kg, were more effective in decreasing the parasite number in the kidney, liver, and spleen. Moreover, BK20 mg/kg and AK10 mg/kg decreased the organs size significantly while AD50 mg/kg and BD40 mg/kg were less effective. However, none of the four nanodrugs had increased the blood factors and they were not toxic. Conclusions: Overall, the pathologic findings of various mice organs treated with different formulations showed that AK10 mg/kg and BK20 mg/kg were more effective in recovery of L. major's pathological effects in comparison to AD50 mg/kg and BD40 mg/kg. Therefore, it seems that AK and BK, in this mentioned dosage, could be considered as a proper candidate for treatment of leishmaniasis.

show abstract

“…In order to get an immunoadjuvant effect to AmB therapy, AmB loaded pluronic F127 (PF 127) micelles were coated with chitosan (Cs-PF-AmB-M), giving them macrophage targeting properties. This formulation was about eight to 10-fold less cytotoxic than AmB suspension [ 82 ]. Flow cytometry revealed that Cs-PF-FITC-M was more internalized by J774A.1 macrophages than PF-FITC-M.…”

Section: Immunomodulatory Effect Of Chitosanmentioning

confidence: 99%

“…In vitro and in vivo antileishmanial activities of Cs-PF-AmB-M were encouraging with a stimulation of a Th1 immune response. The intravenous administration of the formulation had no effect on blood urea nitrogen and plasma creatinine levels and the pharmacokinetic data demonstrated that Cs-PF-AmB-M was able to circumvent the classical AmB nephrotoxicity [ 82 ]. From these results, Cs-PF-AmB-M appears to be a possible formulation candidate combining both immunological and therapeutic targets, without acute toxicity for the treatment of visceral leishmaniasis.…”

Section: Immunomodulatory Effect Of Chitosanmentioning

confidence: 99%

Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis

2020

View full text Add to dashboard Cite

The control of leishmaniases, a complex parasitic disease caused by the protozoan parasite Leishmania, requires continuous innovation at the therapeutic and vaccination levels. Chitosan is a biocompatible polymer administrable via different routes and possessing numerous qualities to be used in the antileishmanial strategies. This review presents recent progress in chitosan research for antileishmanial applications. First data on the mechanism of action of chitosan revealed an optimal in vitro intrinsic activity at acidic pH, high-molecular-weight chitosan being the most efficient form, with an uptake by pinocytosis and an accumulation in the parasitophorous vacuole of Leishmania-infected macrophages. In addition, the immunomodulatory effect of chitosan is an added value both for the treatment of leishmaniasis and the development of innovative vaccines. The advances in chitosan chemistry allows pharmacomodulation on amine groups opening various opportunities for new polymers of different size, and physico-chemical properties adapted to the chosen routes of administration. Different formulations have been studied in experimental leishmaniasis models to cure visceral and cutaneous leishmaniasis, and chitosan can act as a booster through drug combinations with classical drugs, such as amphotericin B. The various architectural possibilities given by chitosan chemistry and pharmaceutical technology pave the way for promising further developments.

show abstract

Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis

Cited by 63 publications

References 31 publications

MicroRNA‐365 promotes the contractile phenotype of venous smooth muscle cells and inhibits neointimal formation in rat vein grafts

MicroRNA‐365 promotes the contractile phenotype of venous smooth muscle cells and inhibits neointimal formation in rat vein grafts

In Vivo Therapeutic Effects of Four Synthesized Antileishmanial Nanodrugs in the Treatment of Leishmaniasis

Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis

Contact Info

Product

Resources

About